About 165 million Americans rely on employer-sponsored health insurance and yet, workers may still not get the coverage they want — particularly when it comes to drugs like Wegovy and Novo Nordisk's diabetes drug Ozempic.
One in three employees are looking for more resources to combat obesity, according to a recent report by consulting firm Gallagher.
Glucagon-like peptide-1 treatments such as Wegovy and Ozempic, which mimic hormones produced in the gut to suppress a person's appetite, are considered game changers on this front.
Already, prescription drug costs jumped 8.6% last year, due in part to a surge in the use of GLP-1 drugs, according to a recent report by Mercer.
"It becomes a lifelong drug," said Gary Kushner, chair and president of Kushner & Company, a benefits design and management company.
Persons:
Gallagher, Trilliant, Mercer, Sunit Patel, actuary, Gary Kushner
Organizations:
Finance, Security, Kushner & Company
Locations:
U.S, Mercer's